Skip to main content

Advertisement

SpringerLink
Log in

The Clinical Efficacy of Influenza Vaccination

  • Section 1: The Rationale for Economic Evaluation of Influenza
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Inactivated influenza vaccine was developed approximately 50 years ago. The formulation has been continually improved, and its efficacy in preventing morbidity in healthy adults repeatedly demonstrated. Whether or not the vaccine is able to prevent hospitalisation and other complications of influenza in older individuals has been resolved by recent observational studies. During periods of influenza virus circulation, the vaccine has also been shown to be effective in preventing hospitalisation and, in some cases, death from all causes and specific causes such as all respiratory conditions. Antivirals are also available for use against type A influenza, and may be especially valuable when antigenic change in the virus occurs. Now that questions regarding clinical effectiveness have been answered, vaccine and antivirals should certainly be more extensively used than in the past. The determinations of positive clinical effectiveness, which are based on observations of actual use of the vaccine, can form a basis for calculation of cost effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davenport FM. Control of influenza, symposium on influenza. Med J Aust Spec 1973; Suppl. 1: 33–8

    Google Scholar 

  2. Monto AS, Olazabel Jr F. Asian influenza in the Panama Canal Zone: isolation of a virus variant and protective effect of a vaccine containing A2/Japan/305/57. Am J Epidemiol 1966; 83: 101–12

    PubMed  CAS  Google Scholar 

  3. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987; 82 Suppl. 6A: 20–5

    Article  Google Scholar 

  4. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunizations Practices (ACIP). MMWR Morb Mortal Wkly Rep 1995; 44 (RR-3): 1–22

  5. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38–44

    Article  PubMed  CAS  Google Scholar 

  6. Phair J, Kauffman CA, Bjornson A, et al. Failure to respond to influenza vaccine in the aged: correlation with B–cell numberand function. J Lab Clin Med 1978; 92: 822–8

    PubMed  CAS  Google Scholar 

  7. Patriarca PA. A randomised controlled trial of influenza vaccine in the elderly. Scientific scrutiny and ethical responsibility. JAMA 1994; 272: 1700–1

    Article  PubMed  CAS  Google Scholar 

  8. Williams WW, Hickson MA, Kane MA, et al. Immunization policies and vaccine coverage among adults. Ann Intern Med 1988; 108: 616–25

    PubMed  CAS  Google Scholar 

  9. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. JAMA 1980; 244: 2547–9

    Article  PubMed  CAS  Google Scholar 

  10. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumoniain the elderly. Am J Epidemiol 1992; 136: 296–307

    PubMed  CAS  Google Scholar 

  11. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol. In press

  12. Office of Technology Assessment, US Congress. Cost effectiveness of influenza vaccination. Washington DC: Government Printing Office, 1982

  13. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956–61

    Article  PubMed  CAS  Google Scholar 

  14. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New Engl J Med 1994; 331: 778–84

    Article  PubMed  CAS  Google Scholar 

  15. Monto AS. Influenza vaccines for the elderly. New Engl J Med 1994; 331: 807–8

    Article  PubMed  CAS  Google Scholar 

  16. Longini Jr IM, Koopman JS, Monto AS, et al. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982; 115: 736–51

    PubMed  Google Scholar 

  17. Longini Jr IM, Monto AS, Koopman JS. Statistical procedures for estimating the community probability of illness in family studies: rhinovirus and influenza. Int J Epidemiol 1984; 13: 99–106

    Article  PubMed  Google Scholar 

  18. Elveback LR, Fox JP, Ackerman E, et al. An influenza simulation model for immunization studies. Am J Epidemiol 1976; 103: 152–65

    PubMed  CAS  Google Scholar 

  19. Monto AS, Davenport FM, Napier JA, et al. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of school children. J Infect Dis 1970; 122: 16–25

    Article  PubMed  CAS  Google Scholar 

  20. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloriderelate to differences in pharmacokinetics. Antimicrob Agents Chemother 1983; 23: 458–64

    Article  PubMed  CAS  Google Scholar 

  21. Monto AS, Gunn RA, Bandyk MG, et al. Prevention of Russian influenza by amantadine. JAMA 1979; 241: 1003–7

    Article  PubMed  CAS  Google Scholar 

  22. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenzaA infection. N Engl J Med 1982; 307: 580–4

    Article  PubMed  CAS  Google Scholar 

  23. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986; 29: 339–41

    Article  PubMed  CAS  Google Scholar 

  24. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine–resistance influenza A virusin families. N Engl J Med 1989; 321: 1696–702

    Article  PubMed  CAS  Google Scholar 

  25. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 1992: 15: 362–7

    Article  PubMed  CAS  Google Scholar 

  26. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A(H3N2) in a nursing home. Arch Intern Med 1988; 148: 865–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Public Health, University of Michigan, Ann Arbor, Michigan, 48109-2029, USA

    Arnold S. Monto (Professor of Epidemiology and International Health)

Authors
  1. Arnold S. Monto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monto, A.S. The Clinical Efficacy of Influenza Vaccination. Pharmacoeconomics 9 (Suppl 3), 16–22 (1996). https://doi.org/10.2165/00019053-199600093-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199600093-00006

Keywords

Search

Navigation